Literature DB >> 33675405

Clostridium butyricum Supernatant Regulates the Expression of RORγt in HCT-116 Cells by Inhibiting the TLR2/MyD88/NF-κB Signaling Pathway.

Ying Xie1, Linyan Zhou1, Hui Li1, Yan Li2.   

Abstract

In this study, we treated HCT-116 cells with Clostridium butyricum (C. butyricum) supernatant and observed its effects on the TLR2/MyD88/NF-κB signaling pathway and RORγt, to further explore the possible immune regulatory mechanism of C. butyricum. Our results showed that C. butyricum supernatant downregulated the mRNA and protein levels of TLR2, MyD88, NF-κBp65, and RORγt in HCT-116 cells and the protein levels of phospho-NF-κBp65. Partial blockage of TLR2 by CD282 weakened the inhibitory effects of C. butyricum supernatant on the above pathway components. Those component levels were still inhibited by C. butyricum supernatant after Pam3CSK4 activation of TLR2. In summary, C. butyricum supernatant can inhibit the TLR2/MyD88/NF-κB signaling pathway and the expression of RORγt in HCT-116 cells. These effects are at least partly achieved through inhibition of TLR2.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33675405     DOI: 10.1007/s00284-021-02392-1

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  30 in total

1.  Preventive efficacy of butyrate enemas and oral administration of Clostridium butyricum M588 in dextran sodium sulfate-induced colitis in rats.

Authors:  T Okamoto; M Sasaki; T Tsujikawa; Y Fujiyama; T Bamba; M Kusunoki
Journal:  J Gastroenterol       Date:  2000       Impact factor: 7.527

2.  Bifidobacteria can protect from enteropathogenic infection through production of acetate.

Authors:  Shinji Fukuda; Hidehiro Toh; Koji Hase; Kenshiro Oshima; Yumiko Nakanishi; Kazutoshi Yoshimura; Toru Tobe; Julie M Clarke; David L Topping; Tohru Suzuki; Todd D Taylor; Kikuji Itoh; Jun Kikuchi; Hidetoshi Morita; Masahira Hattori; Hiroshi Ohno
Journal:  Nature       Date:  2011-01-27       Impact factor: 49.962

3.  Protective Effects of Clostridium Butyricum in a Murine Model of Dextran Sodium Sulfate-Induced Colitis That Involve Inhibition of the TLR2 Signaling Pathway and T Helper 17 Cells.

Authors:  Ying Xie; Linyan Zhou; Xinjie Yao; Yan Li
Journal:  Am J Med Sci       Date:  2020-05-20       Impact factor: 2.378

4.  Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis.

Authors:  Yasushi Yoshimatsu; Akihiro Yamada; Ryuichi Furukawa; Koji Sono; Aisaku Osamura; Kentaro Nakamura; Hiroshi Aoki; Yukiko Tsuda; Nobuo Hosoe; Nobuo Takada; Yasuo Suzuki
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

5.  Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.

Authors:  B J Rembacken; A M Snelling; P M Hawkey; D M Chalmers; A T Axon
Journal:  Lancet       Date:  1999-08-21       Impact factor: 79.321

6.  Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.

Authors:  W Kruis; P Fric; J Pokrotnieks; M Lukás; B Fixa; M Kascák; M A Kamm; J Weismueller; C Beglinger; M Stolte; C Wolff; J Schulze
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

7.  Commercial probiotic bacteria and prebiotic carbohydrates: a fundamental study on prebiotics uptake, antimicrobials production and inhibition of pathogens.

Authors:  Alma Cruz-Guerrero; Humberto Hernández-Sánchez; Gabriela Rodríguez-Serrano; Lorena Gómez-Ruiz; Mariano García-Garibay; Ivonne Figueroa-González
Journal:  J Sci Food Agric       Date:  2014-01-31       Impact factor: 3.638

8.  A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis.

Authors:  Signe Wildt; Inge Nordgaard; Ulla Hansen; Elke Brockmann; Jüri J Rumessen
Journal:  J Crohns Colitis       Date:  2011-01-08       Impact factor: 10.020

9.  Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.

Authors:  Antonio Tursi; Giovanni Brandimarte; Alfredo Papa; Andrea Giglio; Walter Elisei; Gian Marco Giorgetti; Giacomo Forti; Sergio Morini; Cesare Hassan; Maria Antonietta Pistoia; Maria Ester Modeo; Stefano Rodino'; Teresa D'Amico; Ladislava Sebkova; Natale Sacca'; Emilio Di Giulio; Francesco Luzza; Maria Imeneo; Tiziana Larussa; Salvatore Di Rosa; Vito Annese; Silvio Danese; Antonio Gasbarrini
Journal:  Am J Gastroenterol       Date:  2010-06-01       Impact factor: 10.864

10.  Specific immunotherapy ameliorates ulcerative colitis.

Authors:  Min Cai; Lu Zeng; Lin-Jing Li; Li-Hua Mo; Rui-Di Xie; Bai-Sui Feng; Peng-Yuan Zheng; Zhi-Gang Liu; Zhan-Ju Liu; Ping-Chang Yang
Journal:  Allergy Asthma Clin Immunol       Date:  2016-08-05       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.